Literature DB >> 35734010

Hearing aid support for patients with DR-TB in Ethiopia.

G Teferra1, K Teklemariam2, D F Wares3, C Negeri4, A Bedru1.   

Abstract

SETTING: Previous and current patients with drug-resistant TB (DR-TB) who had documented treatment-related hearing impairment due to second-line injectable (SLI) use were identified from different DR-TB treatment initiation centres in Ethiopia.
OBJECTIVE: To assess selected patients with DR-TB for eligibility for hearing aids and provide hearing aids to 10 eligible patients.
DESIGN: This was an observational cohort study. Patients were followed up for 8 months, with hearing assessments conducted at 1, 3 and 8 months to objectively assess hearing capacity.
RESULTS: Of 12 patients assessed for hearing aids eligibility, 10 were fitted with hearing aids (type XTM XP P4) and followed up for 8 months. "Formal" improvement was observed only in one patient. However, "general quality of life" appeared to be improved in nine patients.
CONCLUSION: Minimal "formal" improvement was observed. However, the study was too small to say whether hearing aids should, or should not, be recommended as a public health measure. This needs a larger better controlled follow-up study. The all-oral DR-TB treatment regimens should be used for all patients with DR-TB in Ethiopia. However, as a proportion of patients with DR-TB are likely to continue receiving SLIs in the foreseeable future, they will require close audiometry assessment and appropriate care.
© 2022 The Union.

Entities:  

Keywords:  Challenge TB; bedaquiline introduction; drug-resistant-TB

Year:  2022        PMID: 35734010      PMCID: PMC9176189          DOI: 10.5588/pha.21.0068

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  8 in total

1.  Translations of the International Outcome inventory for Hearing Aids (IOI-HA).

Authors:  Robyn M Cox; Dafydd Stephens; Sophia E Kramer
Journal:  Int J Audiol       Date:  2002-01       Impact factor: 2.117

Review 2.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Ototoxicity of amikacin.

Authors:  R E Black; W K Lau; R J Weinstein; L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

Review 4.  Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.

Authors:  Rohit Sarin; D Behera; Ashwani Khanna; Vikram Singh; Prashant Narang; T S Deepak
Journal:  Indian J Tuberc       Date:  2019-04-11

Review 5.  Hearing loss in patients on treatment for drug-resistant tuberculosis.

Authors:  James A Seddon; Peter Godfrey-Faussett; Kayleen Jacobs; Adam Ebrahim; Anneke C Hesseling; H Simon Schaaf
Journal:  Eur Respir J       Date:  2012-06-14       Impact factor: 16.671

Review 6.  The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Authors:  A Reuter; P Tisile; D von Delft; H Cox; V Cox; L Ditiu; A Garcia-Prats; S Koenig; E Lessem; R Nathavitharana; J A Seddon; J Stillo; A von Delft; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2017-11-01       Impact factor: 2.373

7.  Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.

Authors:  Daniel Meressa; Rocío M Hurtado; Jason R Andrews; Ermias Diro; Kassim Abato; Tewodros Daniel; Paritosh Prasad; Rebekah Prasad; Bekele Fekade; Yared Tedla; Hanan Yusuf; Melaku Tadesse; Dawit Tefera; Abraham Ashenafi; Girma Desta; Getachew Aderaye; Kristian Olson; Sok Thim; Anne E Goldfeld
Journal:  Thorax       Date:  2015-10-27       Impact factor: 9.139

8.  Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.

Authors:  Evans L Sagwa; Nunurai Ruswa; Farai Mavhunga; Timothy Rennie; Hubert G M Leufkens; Aukje K Mantel-Teeuwisse
Journal:  BMC Pharmacol Toxicol       Date:  2015-12-10       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.